Literature DB >> 30479203

State Approaches to Therapeutic Interchange in Community Pharmacy Settings: Legislative and Regulatory Authority.

Thomas Vanderholm1, Donald Klepser2, Alex J Adams3.   

Abstract

Therapeutic interchange is the act of switching a prescribed drug for another drug in the same therapeutic class that is believed to be therapeutically similar but may be chemically different. Therapeutic interchange is different from generic substitution in that it does not occur between therapeutically equivalent products; instead, products are substituted for those that are likely to have a substantially equivalent therapeutic effect generally at a lower cost. Therapeutic interchange is common in institutional settings across the United States but rarely occurs in community pharmacy settings without a pharmacist first contacting the original prescriber and requesting a new prescription in order to facilitate a change. As of 2018, Arkansas, Idaho, and Kentucky have passed laws to enable therapeutic interchange in community pharmacy settings. In general, these laws require the original prescriber to opt-in to allow therapeutic interchange, and the pharmacist generally must leverage the formulary of the patient's health plan to guide decision making within the same therapeutic class. These 3 states require that the pharmacist notify the original prescriber of any interchange in order to ensure a complete and accurate medication record. When appropriately structured, state laws enabling therapeutic interchange in community pharmacy settings allow pharmacists to use their medication expertise to save valuable time and enhance patient care while reducing health care costs. DISCLOSURES: No funding supported the writing of this article. The authors have nothing to disclose.

Entities:  

Mesh:

Year:  2018        PMID: 30479203     DOI: 10.18553/jmcp.2018.24.12.1260

Source DB:  PubMed          Journal:  J Manag Care Spec Pharm


  2 in total

1.  Prescription Adaptation Services: A Win for Patients and Providers.

Authors:  Alex J Adams
Journal:  Innov Pharm       Date:  2020-12-10

2.  Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence Among Older Women With Breast Cancer.

Authors:  Xuanzi Qin; Peter Huckfeldt; Jean Abraham; Douglas Yee; Beth A Virnig
Journal:  J Natl Cancer Inst       Date:  2022-07-11       Impact factor: 11.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.